Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
17 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Adtralza“
Suchtreffer
Begriffe & Kennungen
Adtralza · 4.8 · Conjunctivitis and related events Conjunctivitis occurred more frequently in atopic dermatitis patients who re
Eintrag öffnenAdtralza · 4.8 · Description of selected adverse reactions
Eintrag öffnenAdtralza · 4.8 · Eczema herpeticum Eczema herpeticum was reported in 0.3% of the subjects treated with tralokinumab and in 1.5%
Eintrag öffnenAdtralza · 4.8 · Eosinophilia Adverse reactions of eosinophilia were reported in 1.3% of patients treated with tralokinumab and
Eintrag öffnenAdtralza · 4.8 · Immunogenicity As with all therapeutic proteins, there is a potential for immunogenicity with tralokinumab.
Eintrag öffnenAdtralza · 4.8 · In ECZTRA 1, ECZTRA 2, ECZTRA 3, and the vaccine-response study, the incidence of ADA up to 16 weeks was 1.4%
Eintrag öffnenAdtralza · 4.8 · Injection site reactions Injection site reactions (including pain and redness) occurred more frequently in pat
Eintrag öffnenAdtralza · 4.8 · Keratitis was reported in 0.5% of subjects treated with tralokinumab during the initial treatment period. Of t
Eintrag öffnenAdtralza · 4.8 · Paediatric population
Eintrag öffnenAdtralza · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnenAdtralza · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
Eintrag öffnenAdtralza · 4.8 · Summary of the safety profile
Eintrag öffnenAdtralza · 4.8 · Table 1: List of adverse reactions MedDRA System Frequency Adverse reaction Organ Class Infections and Very co
Eintrag öffnenAdtralza · 4.8 · Tabulated list of adverse reactions
Eintrag öffnenAdtralza · 4.8 · The long-term safety of tralokinumab was assessed in 2 monotherapy studies up to 52 weeks, and in a combinatio
Eintrag öffnenAdtralza · 4.8 · The most common adverse reactions are upper respiratory tract infections (23.4%; mainly reported as common col
Eintrag öffnenAdtralza · 4.8 · The safety of tralokinumab was assessed in patients 12 to 17 years of age (adolescents) with moderate-to-sever
Eintrag öffnen